0001193125-22-083864.txt : 20220324 0001193125-22-083864.hdr.sgml : 20220324 20220324160644 ACCESSION NUMBER: 0001193125-22-083864 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220321 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220324 DATE AS OF CHANGE: 20220324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVITA Medical, Inc. CENTRAL INDEX KEY: 0001762303 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 202578762 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39059 FILM NUMBER: 22766531 BUSINESS ADDRESS: STREET 1: 28159 AVENUE STANFORD STREET 2: SUITE 220 CITY: VALENCIA STATE: CA ZIP: 91355 BUSINESS PHONE: 661-568-1317 MAIL ADDRESS: STREET 1: 28159 AVENUE STANFORD STREET 2: SUITE 220 CITY: VALENCIA STATE: CA ZIP: 91355 FORMER COMPANY: FORMER CONFORMED NAME: Avita Therapeutics, Inc. DATE OF NAME CHANGE: 20200630 FORMER COMPANY: FORMER CONFORMED NAME: Avita Medical, Ltd. DATE OF NAME CHANGE: 20181218 8-K 1 d314378d8k.htm 8-K 8-K
false 0001762303 0001762303 2022-03-21 2022-03-21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 21, 2022

 

 

Avita Medical, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39059   85-1021707

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

28159 Avenue Stanford, Suite 220, Valencia, CA 91355     661.367.9170
(Address of principal executive offices, including Zip Code)     (Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   RCEL   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01.

Other Events.

On March 21, 2022, the Company issued a press release announcing the modification of its contract with the Biomedical Advanced Research and Development Authority (“BARDA”). The modification aims to support the Company’s RECELL® System clinical trial in soft tissue reconstruction. A copy of the press release is attached hereto as Exhibit 99.1.

On March 22, 2022, the Company issued a press release announcing an Investor Webinar led by Dr. Mike Perry, the Company’s CEO, and Michael Holder, the Company’s CFO, on Thursday 24 March 2022 at 11am (AEDT). A copy of the press release is attached hereto as Exhibit 99.2.

On March 23, 2022, the Company issued a press release announcing that an abstract highlighting the clinical trial protocol utilizing the RECELL® Autologous Cell Harvesting Device (RECELL® System) to treat vitiligo will be presented at the Global Vitiligo Foundation Annual Scientific Symposium on March 24, 2022 at 9:38am EDT. A copy of the press release is attached hereto as Exhibit 99.3.

The information under these Items 8.01 and in Item 9.01 below is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

    No.    

   

Description

99.1    AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction
99.2    Investor Webinar Release
99.3    RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
EXHIBIT 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 24, 2022      
    AVITA MEDICAL, INC.
    By:  

/s/ Donna Shiroma

    Name:   Donna Shiroma
    Title:   General Counsel
 EX-99.1 2 d314378dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction

March 21, 2022

Funds will support completion of the ongoing pivotal clinical trial

VALENCIA, Calif. and MELBOURNE, Australia, March 21, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Biomedical Advanced Research and Development Authority (BARDA) has modified its existing contract with the Company to support AVITA Medical’s clinical trial in soft tissue reconstruction. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).

“We are extremely pleased that BARDA is supporting advanced treatment options for soft tissue reconstruction,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “The RECELL System has already proven itself as a safe and effective tool for those with burns, and we are committed to expanding its use to include all acute wounds. We are pleased BARDA recognizes the potential it holds for a broader group of patients experiencing trauma. BARDA has been an outstanding partner, and we are excited to continue our work to expand the indication for the RECELL System with their support.”

Soft tissue reconstruction is of particular concern to BARDA and AVITA Medical, as skin grafting, the current standard of care for soft tissue reconstruction, requires the harvesting of donor skin which can result in an additional wound to the patient. Significant pain, delayed healing, risk of infection, the need for multiple procedures, discoloration and scarring are associated with donor site wounds. While skin grafting is commonly associated with burn treatment, in 2017, approximately 80% of acute wounds that required skin grafting were non-burn related injuries accounting for more than 200,000 procedures in the U.S.i

AVITA Medical is currently completing a pivotal trial for the use of the RECELL System for soft tissue reconstruction. Currently, the RECELL System is indicated in the U.S. for treatment of acute thermal burns. The clinical trial will compare the clinical performance of conventional autografting to that of widely meshed autografting with the RECELL System on acute non-burn full-thickness skin defects, with the goal of demonstrating that less donor skin is needed without compromising healing outcomes. Topline data from the trial will be shared later this year.

AVITA Medical has had a long-term positive relationship with BARDA since September 2015 and was of fundamental importance to the Company being able to achieve premarket approval for the RECELL System in late 2018.

This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201500028C

ABOUT AVITA MEDICAL, INC.

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES ® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical’s first U.S. product, the RECELL ® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018 and a new ease-of-use design was approved in 2022. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our

products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

FOR FURTHER INFORMATION:

 

U.S. Media

Sam Brown, Inc.

Christy Curran

Phone +1-615-414-8668

christycurran@sambrown.com

   

Investors

Westwicke Partners

Caroline Corner

Phone +1-415-202-5678

caroline.corner@westwicke.com

O.U.S. Media

Rudi Michelson

Phone +61 (0)3 9620 3333

Mobile +61 (0)411 402 737

rudim@monsoon.com.au

   

 

i

2017 Procedural Data. © 2019 DR/Decision Resources, LLC

EX-99.2 3 d314378dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

Investor Webinar

VALENCIA, Calif. and MELBOURNE, Australia, 22 March 2022 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, invites shareholders and prospective investors to attend its investor webinar and presentation by Dr. Mike Perry, CEO, and Michael Holder, CFO, on Thursday at 11am (AEDT) 24 March 2022.

The webinar will cover highlights from AVITA Medical’s successful 2021 calendar year, multiple key accomplishments as previously announced over the past quarter and to date, and planned upcoming company milestones.

Interested parties can register for the webinar using this link: https://zoom.us/webinar/register/WN_LgAAB_tyQGS6vyEPG1yAgw

Participants may submit questions during registration or during the session. A replay will be available on the AVITA Medical website, www.avitamedical.com following the presentation.

# # #

ABOUT AVITA MEDICAL, INC.

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE—RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

FOR FURTHER INFORMATION:

 

U.S. Media

Sam Brown, Inc.

Christy Curran

Phone +1-615-414-8668

christycurran@sambrown.com

 

O.U.S Media

Rudi Michelson

Phone +61 (0)3 9620 3333

Mobile +61 (0)411 402 737

rudim@monsoon.com.au

   

Investors:

Westwicke Partners

Caroline Corner

Phone +1-415-202-5678

caroline.corner@westwicke.com

# # #

EX-99.3 4 d314378dex993.htm EX-99.3 EX-99.3

Exhibit 99.3

 

LOGO     

RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the

Global Vitiligo Foundation Annual Scientific Symposium

VALENCIA, Calif. and MELBOURNE, Australia, 23 March 2022 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that an abstract highlighting the clinical trial protocol utilizing the RECELL® Autologous Cell Harvesting Device (RECELL® System) to treat vitiligo will be presented at the Global Vitiligo Foundation Annual Scientific Symposium. The conference is being held in Boston and will highlight research and knowledge of both up and coming vitiligo researchers and those who have and continue to build the foundational knowledge about vitiligo.

“We are pleased to share our clinical study protocol, which aims to establish safety and effectiveness for repigmentation of stable vitiligo lesions utilizing the RECELL System, with leaders of the vitiligo community,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “With enrollment of our vitiligo pivotal trial complete, we look forward to sharing results of our blinded, randomized study in the near future and working with the FDA to bring our novel treatment option to patients.”

RECELL System Abstract

 

  •  

March 24 at 9:38am, Abstract #4: RECELL Autologous Cell Harvesting Device: A Review of the Science of Autologous Skin Cell Suspension and Clinical Protocol Aimed in Establishing Safety and Effectiveness for Repigmentation of Stable Vitiligo Lesions. Authors: K. Bush, A. Hopkin, E. Kirshner, A. Quick

Vitiligo is a disease that attacks pigment-producing cells, called melanocytes, resulting in their destruction or malfunction. The result is a loss of pigmentation in patches of skin. Vitiligo affects up to 2% of the population worldwide,i including an estimated 3-6.5 million Americans.ii Vitiligo has a comparable market size and psychosocial impact to other major dermatology diseases including psoriasis (thick, scaly skin) and atopic dermatitis (red, cracked skin).iii iv v Like these diseases, those living with vitiligo may suffer from poor body image along with low self-esteem, leading to an impaired quality of life.

# # #

ABOUT AVITA MEDICAL, INC. AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived

 

AVITA Medical Inc, 28159 Avenue Stanford, Valencia, CA 91355

Page 1

from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018 and a new ease-of-use design was approved in 2022. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE—RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

 

AVITA Medical Inc, 28159 Avenue Stanford, Valencia, CA 91355

Page 2

FOR FURTHER INFORMATION:

 

U.S. Media

Sam Brown, Inc.

Christy Curran

Phone +1-615-414-8668

christycurran@sambrown.com

 

O.U.S. Media

Rudi Michelson

Phone +61 (0)3 9620 3333

Mobile +61 (0)411 402 737

rudim@monsoon.com.au

   

Investors

Westwicke Partners

Caroline Corner

Phone +1-415-202-5678

caroline.corner@westwicke.com

PR20222303

# # #

 

i 

Picardo et al. Vitiligo. Nature Reviews Disease Primers. 2015.

ii 

John Harris, MD, PhD – Presentation as part of Incyte Corporate presentation. (Harris, UMass, is a global leader in Vitiligo; AVITA collaborator). https://investor.incyte.com/static-files/01f77a1c-6351-4348-adc2-597e2bc1f42eSERT

iii 

National Psoriasis Foundation – Statistics, https://www.psoriasis.org/psoriasis-statistics/ Accessed 10/5/2020

iv 

The burden of vitiligo: Patient characteristics associated with quality of life. Homan, et al. JAAD. 2009

v 

Comparison of the Psychological Impacts of Asymptomatic and Symptomatic Cutaneous Diseases: Vitiligo and Atopic Dermatitis.Noh, et al. Annals of Derm. 2013

 

AVITA Medical Inc, 28159 Avenue Stanford, Valencia, CA 91355

Page 3

EX-101.SCH 5 rcel-20220321.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 rcel-20220321_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 7 rcel-20220321_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 g314378g0324014400285.jpg GRAPHIC begin 644 g314378g0324014400285.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Mar. 21, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001762303
Document Type 8-K
Document Period End Date Mar. 21, 2022
Entity Registrant Name Avita Medical, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39059
Entity Tax Identification Number 85-1021707
Entity Address, Address Line One 28159 Avenue Stanford
Entity Address, Address Line Two Suite 220
Entity Address, City or Town Valencia
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91355
City Area Code 661
Local Phone Number 367.9170
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol RCEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 10 d314378d8k_htm.xml IDEA: XBRL DOCUMENT 0001762303 2022-03-21 2022-03-21 false 0001762303 8-K 2022-03-21 Avita Medical, Inc. DE 001-39059 85-1021707 28159 Avenue Stanford Suite 220 Valencia CA 91355 661 367.9170 false false false false Common Stock, par value $0.0001 per share RCEL NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d314378d8k.htm d314378dex991.htm d314378dex992.htm d314378dex993.htm rcel-20220321.xsd rcel-20220321_lab.xml rcel-20220321_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d314378d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d314378d8k.htm" ] }, "labelLink": { "local": [ "rcel-20220321_lab.xml" ] }, "presentationLink": { "local": [ "rcel-20220321_pre.xml" ] }, "schema": { "local": [ "rcel-20220321.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rcel", "nsuri": "http://avitamedical.com/20220321", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d314378d8k.htm", "contextRef": "duration_2022-03-21_to_2022-03-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d314378d8k.htm", "contextRef": "duration_2022-03-21_to_2022-03-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://avitamedical.com//20220321/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001193125-22-083864-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-083864-xbrl.zip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end